Compare United States Brent Oil Fund LP (BNO) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Brent Oil Fund LP vs Charles River Laboratories Intl. Inc — how do they compare? United States Brent Oil Fund LP trades at $50.68, while Charles River Laboratories Intl. Inc trades at $287.31 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, United States Brent Oil Fund LP nearer its low. Which is the better fit depends on your goals.
| BNO | CRL | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $282.00 |
52-Week Low | $27.20 | $145.57 |
Market Cap | — | $13.46B |
Enterprise Value | — | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNO is trading at $50.505, up 0.79% with a bullish technical outlook supported by moving averages. The oil market faces significant supply disruptions from Middle East tensions, particularly the Strait of Hormuz closure, creating volatility. Recent OPEC demand forecast cuts contrast with supply constraints, creating a complex fundamental backdrop for oil-related securities.
The stock presents opportunity from ongoing supply constraints but faces headwinds from demand destruction and inventory builds. Key risks include geopolitical resolution and demand volatility. Technical momentum remains positive near-term, but fundamental uncertainties require careful monitoring of oil market developments.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
